Management of the patient with Barrett's esophagus: A continuing dilemma for the clinician

Reviews in Gastroenterological Disorders

Volumn 4, Issue 2, 2004, Pages 49-59

  Katz, Philip O ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Ablation; Adenocarcinoma; Antireflux surgery; Antisecretory therapy; Barrett's esophagus; Diagnosis; Endoscopic mucosal resection; Gastroesophageal reflux disease; High grade dysplasia; Surveillance

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; CISAPRIDE; CYCLOOXYGENASE 1 INHIBITOR; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHOTOSENSITIZING AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; STOMACH SECRETION INHIBITOR;

ADENOCARCINOMA; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CANCER SCREENING; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG MEGADOSE; DYSPLASIA; ESOPHAGOSCOPY; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; ESOPHAGUS PH; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; REMISSION; REVIEW; SCREENING TEST; STOMACH ACID SECRETION; THORAX PAIN; COMPARATIVE STUDY; DRUG COMBINATION; ESOPHAGUS TUMOR; FEMALE; GASTROENTEROLOGY; HOSPITALIZATION; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRECANCER; PROGNOSIS; STANDARD; STOMACH FUNDOPLICATION; TREATMENT OUTCOME;

ADENOCARCINOMA; BARRETT ESOPHAGUS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FEMALE; FUNDOPLICATION; GASTROENTEROLOGY; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; PRECANCEROUS CONDITIONS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 2942638010     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Weinstein WM, Ippoliti AF. The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest Endosc. 1996;44:91-95.
2. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
3. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340:825-831.
4. Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 1997;92:1293-1297.
5. Sharma P, Mayo M, Topalovski M, Weston AP. Methylene blue chromoendoscopy for the detection of patients with short-segment Barrett's esophagus. Gastrointest Endosc. 2001;54:289-293.
6. Canto MI, Setrakian S, Willis J, et al. Methylene-blue directed biopsies can improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gastrointest Endosc. 2000;51:560-568.
7. Connor MJ, Sharma P. Chromoendoscopy and magnification endoscopy in Barrett's esophagus. Gastrointest Clin N Am. 2003; 13:269-277.
8. Poneros JM, Brand S, Bouman BE, et al. Diagnosis of specialized intestinal metaplasia by optical coherence tomography. Gastroenterology. 2001;120:7-12.
9. McClave SA, Boyce HW, Gottfried MR. Early diagnosis of columnar-lined esophagus: a new endoscopic criterion. Gastrointest Endosc. 1987;33:413-416.
10. Sharma P, Weston AP, Morales T, et al. Relative risk of dysplasia for patients with intestinal metaplasia in distal esophagus and gastric cardia. Gut. 2000;46:9-13.
11. Lieberman DA, Oehlke M, Helfand M, et al. Risk factors for Barrett's esophagus in community-based practice. Am J Gastroenterol. 1997; 92:1293-1297.
12. Sharma P. Risk of cancer in Barrett's esophagus. Clin Perspect Gastroenterol. 2002;5:248-250.
13. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology. 1998;115:50-57.
14. Coenraad M, Masclee A, Straathof JW, et al. Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis? Am J Gastroenterol. 1998;93:1068-1072.
15. Stein HJ, Joeft S, DeMeester TR. Functional foregut abnormalities in Barrett's esophagus. J Thorac Cardiovasc Sury. 1993;105:107-111.
16. Frazzoni M, DeMicheli E, Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther. 2003; 18:1091-1098.
17. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996;111:1192-1199.
18. Shaheen NJ, Crosby MA, Bozymski EM. Is there publication bias in the reporting of cancer risk of Barrett's esophagus? Gastroenterology. 2000;119:333-338.
19. Reid B, Prevo L, Galipeau P, et al. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839-2848.
20. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology. 1992;102:1212-1219.
21. Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol. 2001;96:990-996.
22. Ouatu-Lascar R, Trjadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1998;93:711-716.
23. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1995;90:672-673.
24. Fass R, Sampliner RE, Malagon IB, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reverral on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther. 2000;14:597-602.
25. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus: an ex-vivo proliferation and differentiation model. J Clin Invest. 1996;98:2120-2128.
26. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology. 1999;117:327-335.
27. Gore S, Healy LJ, Sutton R, et al. Regression of columnar-lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther. 1993;76:623-628.
28. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol. 1994;89:1844-1848.
29. Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther. 1995;9:451-454.
30. Peters FTM, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment: a randomized double-blind study. Gut. 1999;45:489-494.
31. Srinivasan R, Katz PO, Ramakrishnan A, et al. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther. 2001;15:519-524.
32. Aguirre T, El-Serag H, Davis S, et al. Proton pump inhibitors reduce the incidence of dysplasia in Barrett's esophagus [abstract]. Am J Gastroenterol. 2003;98:S23.
33. Ours TM, Falk GW, Richter JE, Vaezi M. Can we normalize esophageal acid and bile exposure in patients with Barrett's esophagus using proton pump inhibitors? [abstract]. Am J Gastroenterol. 2002;97:S22.
34. Sharma P, Reker D, Weston A, et al. Normalization of intra-esophageal pH in patients with Barrett's esophagus (BE) on rabeprazole and relationship of pH to Barrett's length and hiatal hernia [abstract]. Am J Gastroenterol. 2002;97:S37.
35. Ahmad F, Banerjee P, Tutuian R, et al. Control of esophageal acid exposure in Barrett's-many ways to skin a cat! [abstract]. Am J Gastroenterol. 2003;98:S5.
36. Katz PO, Castell DO, Chen Y, Sostek SB. Esomeprazole provides highly effective acid control that is equally well maintained during sleep and active periods [abstract]. Am J Gastroenterol. 2003;98:S15.
37. Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after surgery. Gastroenterology. 2001;121:1286-1293.
38. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. Follow up of a randomized controlled trial. JAMA. 2001; 285:2331-2338.
39. Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol. 2003;98:2390-2394.
40. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology. 2002; 123:461-467.
41. Ward EM, DeVault KR, Wolfsen HC, et al. Barrett's esophagus in unscreened, older patients undergoing screening or follow-up colonoscopy [abstract]. Gastroenterology. 2003; 124(suppl 1):A642.
42. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heart-burn. Gastroenterology. 2003;125:1670-1677.
43. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett's esophagus in high-risk groups: a cost utility analysis. Ann Intern Med. 2003;138:176-186.
44. Dean R, Dua K, Massey B, et al. A comparative study of unsedated transnasal esophagogastroduodenoscopy and conventional EGD. Gastrointest Endosc. 1996;44:422-424.
45. Saeian K, Staff DM, Vasilopoulos S, et al. Unsedated transnasal endoscopy accurately detects Barrett's metaplasia and dysplasia. Gastrointest Endosc. 2002;56:472-478.
46. Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett's adenocarcinoma. Gastroenterology. 2002;122:633-640.
47. Cooper GS, Yuan Z, Chak A, et al. Association of prediagnosis endoscopy with stage and survival in adenocarcinorna of the esophagus and gastric cardia. Cancer. 2002;95:32-38.
48. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607-1619.
49. Robertson CS, Mayberry JF, Nicholson DA, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagitis. Br J Surg. 1988;75:760-763.
50. Hameteman W, Tytgat NJ, Houthoff HJ, van den Tweek JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249-1256.
51. Miros M, Kerlin MM, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut. 1991;32:1441-1446.
52. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000;95:1669-1676.
53. Hamilton SR, Smith RR. The relationship between columnar epithelial hyperplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol. 1987;87:301-312.
54. Lee RG. Dysplasia in Barrett's esophagus. A clinicopathologic study in six patients. Am J Surg Pathol. 1985;9:845-852.
55. Rice TW, Falk GW, Achkar E, Petras RE. Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol. 1993;88:1832-1836.
56. Pera M, Trastek VF, Carpenter HA, et al. Is Barrett's esophagus with high-grade dysplasia an indication for esophagectomy? Ann Thorac Surg. 1992;54:199-204.
57. Edwards MJ, Gable DR, Lentsch AB, Richardson JD. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high grade dysplasia. Ann Surg. 1996; 223:585-589.
58. Patti MG, Corvera CU, Glasgow RE, Way LW. A hospital's annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg. 1998;2:186-192.
59. Birkmeyer JD, Siewers AE, Finalyson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002; 346:1128-1137.
60. Levine DS, Haggitt RC, Blount PL, et al. An endoscopic protocol can differentiate high grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology. 1993;105:40-50.
61. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607-1619.
62. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120:1630-1639.
63. Wang KK. Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc. 1999;49:S20-S23.
64. Overholt BF, Lightdale CJ, Wang K, et al. International, multicenter, partially blinded, randomised study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (POR) for the ablation of high-grade dysplasia (HGD) in Barrett's esophagus (BE). Results of 24-month follow-up [abstract]. Gastroenterology. 2003;124:A20.
65. Attwood SEA, Lewis CJ, Caplin S, et al. Argon bean plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol. 2003;1;258-263.
66. Pacifico RJ, Wang KK, Wongkeesong LM, et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol. 2003;1:252-257.
67. Buttar NS, Wang KK, Burgart LJ, et al. Endoscopic appearance and extent of high-grade dysplasia in Barrett's esophagus can predict the presence of cancer at esophagectomy [abstract]. Am J Gastroenterol. 2003;98:S28.